Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Commvault Systems Inc (CVLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Commvault Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Commvault Systems Inc trades at $141.97 (market cap $5.78B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.1× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CVLT | |
|---|---|---|
Market Cap | $29.60B | $5.78B |
Sector | Health | Technology |
52-Week High | $491.22 | $195.41 |
52-Week Low | $205.48 | $75.18 |
Enterprise Value | $27.56B | $5.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Commvault Systems (CVLT) trades at $141.74, up 1.66% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.42 per share, beating estimates, and has a consensus analyst price target of $172.40. Revenue growth is robust, with 2026 projections at $1.2 billion, though net income margin is expected to compress. Recent news includes a shareholder investigation and positive developments in threat scan integration.
The outlook is positive given earnings beats and subscription growth, but high valuation ratios (P/E of 89.35) and margin pressure pose risks. Investor sentiment is buoyed by analyst buy ratings (54.55%), though legal scrutiny and competitive threats require monitoring for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →
